İDİYOPATİK TROMBSİTOPENİK PURPURA’YA YAKLAŞIM VE TEDAVİ

Öz

Idiopathic thrombocytopenic purpura ITP is a disease known to have medical and surgical treatments. Although ITP is a benign disease, it is associated with high morbidity and mortality, especially in refractory cases. With the advent of thrombopoietic agents in recent years AMG 531 and eltrombopag , it is appropriate to re-evaluate the management and treatment of ITP. Ideally, treatment of ITP should be based on the underlying pathophysiology

Anahtar Kelimeler

• İmmunglobulin,ortalama trombosit volümü,diyabetik komplikasyonlar

MANAGEMENT AND TREATMENT OF IDİOPATHİC THROMBOCYTOPENİC PURPURA

Öz

Idiopatik trombositopenik purpura ITP medikal veya cerrahi olarak tedavi edilebilen bir hastalıktır.ITP genellikle selim gidişli bir hastalık olmasına karşın özellikle dirençli olgularda yüksek morbidite ve mortalite nedeni olmaktadır.Son yıllarda yeni trombopoietik ajanların AMG 531 ve eltrombopag kullanılması nedeniyle ITP’nin yeniden değerlendirilme ve tedavisi gereksinimi doğmuştur..ITP’nin ideal tedavisi altta yatan patolojiye yönelik olmalıdır

Anahtar Kelimeler

• Purpura trombositopenik,idiyopatik

Kaynakça

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practical guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
2. Bethel FH, Meyers MC, Millers S, et al. Effects of ACTH and cortisone on idiopathic thrombocytopenic purpura. Trans Assoc Am Physicians 1951;64:199-203.
3. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-913.
4. Stasi R, Provan D. Management of immun thrombocytopenic purpura in adults. Mayo Clinic Proc 2004;79:504-522.
5. Lazarus AH, Crow AR. Mechanism of action of IVIG and Anti-D in ITP. Transfus Apher Sci 2003;28:249-255.
6. Scaradavuo A, Woo B, Woloski BM,et al. Intravenous Anti-D treatment of immun thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-2700.
7. Kojouri K, Vesely SK, Terrell DR,et el. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response and surgical complications. Blood 2004;104:2623-2634.
8. Stasi R, Stipa E, Masi M,et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-442.

9. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immun thrombocytopenic purpura.Br J Haematol 2004;125:232-239.
10. Bilgir O, Bilgir F, Calan M,et al. Immunoabsorption method using immunoglobulin Adsopak in adult cases with ITP resistant to splenectomy and other medical therapies. Transfus Apher Sci 2008;39:109-113.
11. Newland A, Caulier MT, Kappers-Klunne M,et al. An open label, unit dose-finding study of AMG 531, a novel thrombopoiesis- stimulating peptibody, in patients with immun thrombocytopenic purpura.Br J Haematol 2006;135:547-553.
12. Bussel JB, Cheng G, Saleh MN,et el. Eltrombopag for the treatment of chronic idiopathic purpura NEJM 2007;357:2237-2247.
13. McMillan R, Wang L, Tani P, Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003;1:485-491.
14. Stockelberg D, Hou M, Jacobsson S,et al. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996;56:72-77.
15. Kuwana M, Kaburaki J, Kitasato H,et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura.Blood 2001;98:130-139.
16. Olsson B, Andersson PO, Jernas M,et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Med 2003;1123-1124.
17. Filion MC, Proulx C, Bradly AJ,et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membran antigen present on bone marrow-derived cells.Blood 1996;88:2144-2150.
18. 18. Solanilla A, Pasquet JM, Viallard JF,et al. Platelet-associated CD154in immune thrombocytopenic purpura. Blood 2005;105:215-218.
19. Chang M, Nakagawa PA, Williams SA,et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887-895.
20. Cohen YC, Djulbegovic B, Shamai-Lubovitz O,et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistant low platelet counts Arch Intern Med 2000;160:1630-1638.
21. Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: Results in 490 cases. Haematologica 1993;78:22-28.
22. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0) (D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-1537.
23. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really now? Transfus Med Rev.2008;22(2):103-116.
24. Rodeghiero F, Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol.2008;83:91.
25. Schwartz J, Leber MD, Gillis S, et al. Long-term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).Am J Hematol.2003;72:94-98.
26. Onel K, Bussel JB. Adverse effects of estrogen therapy in a subset of women with ITP J Thromb Haemostasis 2004;2:670-671.
27. Kaslow RA, Phair JP, Friedman HB, et al. Infection with the human ımmunodeficiency virus:clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study.Ann Intern Med 1987;107:474-480.
28. McHutchison JK, Dusheiko G, Shiffman ML,et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.NEJM 2007;357:2227-2236.
29. Levy AS, Bussel JB. Immune thrombocytopenic purpura: investigation of the role of cytomegalovirus infection. Br J Haematol.2004;126:622-623.
30. Kuwana M, Ikeda Y. Helicobacter pylori and immun thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol.2006;84:309-315.
31. Arnold D, Dentali F, Crowther M,et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.Ann Intern Med.2007;146:25-33.
32. Godeau B, Fain O, Porcher R,et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: Results of a multicenter prospective phase 2 study. Blood 2006;108:Abstract 478.
33. Boruchov DM, Gururangan S, Driscoll MC et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP) Blood 2007;110:3526-3531.
34. McMillan R, Wang L, Tomer A,et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-1369.
35. Nomura S, Dan K, Hotta T, et al. Effect of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-730.
36. Li J, Yang C, Xia Y,et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248.
37. Bussel JB, Kuter DJ, George JN,et al. AMG 531 a thrombopoiesis-stimulating protein, for chronic ITP. NEJM 2006;355:1672-1681.
38. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
39. Kuter DJ. New thrombopoietic growth factors.Blood 2007;109:4607-4616.